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Abstract
Catechol O-methyltransferase (COMT)-catalyzed methylation of catecholestrogens has been
proposed to play a protective role in estrogen-induced genotoxic carcinogenesis. We have taken a
comprehensive approach to test the hypothesis that genetic variation in COMT might influence breast
cancer risk. Fifteen COMT SNPs selected on the basis of in-depth resequencing of the COMT gene
were genotyped in 1482 DNA samples from a Mayo Clinic breast cancer case-control study. Two
common SNPs in the distal promoter for membrane-bound (MB) COMT, rs2020917 and rs737865,
were associated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study,
with allele-specific odds ratios of 0.70 (95% CI = 0.52–0.95) and 0.68 (95% CI = 0.51–0.92),
respectively. These two SNPs were then subjected to functional genomic analysis and were
genotyped in an additional 3683 DNA samples from two independent case-control studies (GENICA
and GESBC). Functional genomic experiments showed that these SNPs could up-regulate
transcription and that they altered DNA-protein binding patterns. Furthermore, substrate kinetic and
exon array analyses suggested a role for MB-COMT in catecholestrogen inactivation. The GENICA
results were similar to the Mayo case-control observations, with ORs of 0.85 (95% CI = 0.72–1.00)
and 0.85 (95% CI = 0.72–1.01) for the two SNPs. No significant effect was observed in the GESBC
study. These studies demonstrated that two SNPs in the COMT distal promoter were associated with
breast cancer risk reduction in 2 of 3 case-control studies, compatible with the results of functional
genomic experiments, suggesting a role for MB-COMT in breast cancer risk.
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Introduction
Breast cancer is the most common cancer and the second leading cause of cancer death in
women (1). Life-time estrogen exposure is a major risk factor for breast cancer (2,3). Estrogens
can potentially induce carcinogenesis through both receptor-mediated and non-receptor
mediated pathways (4–6) (Fig. 1). This latter pathway is thought to involve metabolic
activation, during which estrogens are metabolized by cytochrome P450 enzymes to form
catecholestrogens which can then converted to estrogen quinones capable of forming stable or
depurinating DNA adducts, resulting in genotoxicity (5,7). Since 4-OH catecholestrogens are
also potent ER ligands (8,9), catecholestrogens could potentially influence both pathways for
estrogen carcinogenesis. Catechol O-methyltransferase (EC2.1.1.6; COMT) catalyzes the
methylation of catechols, including catecholestrogens (10,11). In addition, 2-methoxy
catecholestrogens also have strong anti-carcinogenic effects (12). Therefore, decreased COMT
activity might be a risk factor for breast cancer while elevated activity would, in theory, be
protective.
COMT encodes two isoforms, a soluble cytoplasmic (S-COMT) and a membrane-bound
isoform (MB-COMT) (14,15) (Fig. 2A). A “proximal promoter” in intron 2 drives S-COMT
transcription, while a “distal promoter”, 20 kb upstream at the 5′-end of the gene, does the same
for MB-COMT (14,15). The two COMT isoforms differ only by an additional 50 hydrophobic
amino acids at the N-terminus of MB-COMT (14,15). MB-COMT is believed to be the
dominant isoform in the brain, while S-COMT predominates in peripheral tissues (14–16).
We first described the autosomal co-dominant inheritance of S-COMT activity 30 years ago
(17,18), and its genetic basis was subsequently shown to result, in part, from a nonsynonymous
G to A polymorphism that changes a Val to Met at codon 108 for S-COMT and codon 158 for
MB-COMT (19). The Met108/158 allele is associated with decreased enzyme activity and
decreased thermal stability, both in vitro and in vivo (17,18,20–22). During the past decade,
over 40 epidemiologic studies have been performed to test the possible association of COMT
sequence variation with breast cancer risk. Nearly all of those studies have focused on only the
Val108/158Met polymorphism, but the results have been inconsistent (23–25).
In the present study, we took a systematic approach to test the hypothesis that genetic
polymorphisms in COMT might influence breast cancer risk. We began by resequencing the
gene to determine the spectrum of common variation in COMT (Fig. 2A). Fifteen COMT
polymorphisms were then chosen to genotype DNA samples from a large Mayo Clinic breast
cancer case-control study – followed by functional studies of polymorphisms that appeared to
be associated with risk. We then performed two separate replication studies to test the observed
association. This comprehensive approach resulted in the identification of two polymorphisms
in the distal promoter of COMT that were associated with decreased breast cancer risk in two
of the three studies – an association strongly supported by the functional genomic results –
suggesting that MB-COMT might play a role in catecholestrogen metabolism in breast cancer.
Therefore, our study strongly suggests that these MB-COMT SNPs may represent another of
an increasing number of common polymorphisms that influence breast cancer risk (26).
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Materials and Methods
SNP Selection for Genotyping
COMT was resequenced using DNA from 60 Caucasian-American subjects for all exons,
splice-junctions, intron 2 (22) and 1 kb on either side of exon 11. The COMT consensus
sequence used in our studies was that of contig NT_011519.10. Numbering of nucleotides
within the coding region began at the “A” in the “ATG” for MB-COMT, with nucleotides 3′
to that position assigned positive numbers. Nucleotides located within the two upstream non-
coding exons, and the 5′-FR were assigned negative numbers, with the final nucleotide of exon
2 designed “-1” (i.e., the nucleotide 5′ of the “ATG” start codon). Nucleotides located within
introns were numbered on the basis of distance from the nearest splice site, using positive and
negative numbers for distance to 5′- and 3′-splice sites, respectively. The numbering scheme
for amino acids was based on their distance from the MB-COMT translation start codon. SNPs
included in the genotyping studies were selected either by use of haplotype-tagging (27) or the
LD-select method (28). Fifteen SNPs were selected in this fashion or on the basis of previous
reports of their association with clinical phenotypes (29,30).
Study Populations
Mayo Clinic breast cancer case-control study—The Mayo Clinic study is an
unselected, clinic-based series of breast cancer cases and healthy controls recruited in the Mayo
Clinic Department of Oncology (31). Cases had a diagnosis of histologically confirmed
primary breast cancer within 6 months of enrollment and no prior history of cancer (except for
non-melanoma skin cancer). Controls were frequency matched to cases on county of residence
and five-year age group and were selected from women visiting the Mayo Clinic for a general
medical examination. “Postmenopausal” was defined as having no menstrual period for 12
months or having had the uterus and/or ovaries removed. Family history of cancer was reported
for all first and second degree relatives. Controls were ineligible if they had a previous diagnosis
of cancer (except non-melanoma skin cancer). As of June 2005 when the present study began,
750 cases and 732 controls, entirely Caucasian, had been recruited from the states of Iowa,
Minnesota or Wisconsin. Participation rates were 70% among cases and 72% among controls.
All eligible women were asked to provide written informed consent, risk factor information
via a written questionnaire, and a sample of blood. The study was reviewed and approved by
the Mayo Clinic Institutional Review Board.
The Interdisciplinary Study Group on Gene Environment Interactions and
Breast Cancer in Germany Study Population (GENICA Study)—The GENICA study
is a study of breast cancer cases and controls from the greater Bonn area in Germany (32).
Specially, between August 2000 and September 2004, 1143 breast cancer cases and 1155
population-based controls were recruited. Cases had a first-time diagnosis of primary breast
cancer that was histologically confirmed within 6 months of enrollment. Controls were
population-based and matched to cases in 5-year age groups. All participants were Caucasian
and were <80 years of age. Risk factor information was collected via in-person interviews
using the core questionnaire of a German population survey that had been extended by the
inclusion of questions on factors related to breast cancer. The response rates were 86% for
cases and 69% for controls. A participant was classified as premenopausal if she reported
menstrual periods in the year of interview. All participants provided a blood sample, and DNA
was available for 1015 cases and 1021 controls. The GENICA study was reviewed and
approved by the Ethics Committee of the University of Bonn; and all study participants
provided written informed consent.
1J. Zhang, et al. Catechol O-Methyltransferase Pharmacogenomics: Human Liver Genotype-Phenotype Correlation and Proximal
Promoter Studies. Submitted to “Pharmacogenetics and Genomics”.
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The Genetic Epidemiology Study of Breast Cancer by Age 50 (GESBC)—The
GESBC is a population-based case-control study carried out in two geographical areas of
Germany (Freiburg and the Rhein-Neckar-Odenwald regions) that included patients newly
diagnosed with breast cancer between 1992 and 1995 (33). Subjects were German speaking
(97% had two, and 3% one German parent), under 51 years of age, and they could have no
previous history of breast cancer. Cases had a confirmed diagnosis of either in situ or invasive
breast cancer and were identified by monitoring approximately 40 hospitals. Participation was
70% among the 1005 eligible and living cases. An attempt was made to recruit two population
controls per case, matched by age and study region. Subjects were not eligible to be controls
if they could not speak German, had moved out of the study region, or had a previous history
of primary breast cancer. Participation was 61% among the 2257 eligible population controls.
Subjects were defined as postmenopausal if they reported a natural menopause 6 months before
the reference date (date of diagnosis or date of questionnaire for control) or a bilateral
oophorectomy. The menopausal status of women who reported hysterectomy alone was
classified as unknown. Subjects were asked to complete a self-administered questionnaire on
demographic and breast cancer risk factors, and to provide a blood sample. The GESBC study
was reviewed and approved by the Ethics Committee of the University of Heidelberg, and
subjects who participated provided written informed consent.
Genotyping Methods
Fifteen COMT polymorphisms were used to genotype samples from the Mayo Clinic study.
Most genotyping was performed with the SNPstream platform (Beckman Coulter, Fullerton,
CA). ABI fragment analysis assay was used to genotype the insertion/deletion polymorphism
at COMT 3′-UTR(820), and DNA sequencing was used to genotype five SNPs: 5′-FR(-1420),
5′-FR(-628), 5′-FR(-485), I2(832) and I2(1140). During the two replication studies, only 3
SNPs, 5′-FR(-628), I1(701) and the exon 4(472) Val108/158Met polymorphism, were
genotyped. The GENICA samples was genotyped using Sequenom MALDI-TOF MS (34).
TaqMan technology was used to genotype the GESBC samples (35).
Statistical Analysis
Demographic information for cases and controls was summarized using means and standard
deviations, or counts and percentages, as appropriate. Comparisons were made between case
and control groups using t-tests or chi-square tests. Genotypes for each of the polymorphisms
were used to estimate allele frequencies separately for cases and controls. Genotypes in the
controls were also assessed for departures from Hardy-Weinberg equilibrium.
For the Mayo Clinic study, the association of each SNP genotype with case/control status was
performed separately for pre- and postmenopausal strata. Within each stratum, unconditional
logistic regression was used to evaluate the log-additive effects of the rare allele for each SNP,
while adjusting for age and geographical region of residence. The log-additive effects were
summarized by odds ratios (ORs), and 95% confidence intervals (95% CIs).
In addition to the matching variables, the effects of other covariates were evaluated using
backward stepwise regression, and the additional significant covariates (p-value < 0.05) were
parity/age at first child birth and physical activity. These additional covariates were also used
for statistical adjustments in the logistic regression analyses. Although there have been a large
number of studies of the effect of COMT on breast cancer risk, making the need to control for
multiple testing for our study debatable, we nonetheless present p-values adjusted for multiple
testing of 30 tests (15 SNPs and 2 menopausal strata). To adjust p-values, we randomly
permuted case/control status within each menopausal-status stratum 10,000 times to determine
the distribution of the test statistics. The frequency that the largest permuted statistic (out of
30) was greater than each of the observed statistics provided an empirical p-value adjusted for
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the 30 tests performed. Supplemental analyses were used to evaluate the association of SNP
genotypes with estrogen receptor (ER) status by directly comparing the ER(+) cases versus the
ER(−) cases, once again using logistic regression with covariates.
For the GENICA and GESBC studies, backward covariate selection was used to choose the
covariates HRT and physical activity for the GENICA study and physical activity and parity/
age at first birth for the GESBC study. To perform pooled analyses across all three studies,
relevant covariates were included as fixed effects and the study was included as a random
effect, fitting the models with the SAS NLMIXED procedure. Analyses were performed in the
SAS (SAS Institute, Cary, NC), S-Plus (Insightful, Seattle, WA) and Haploview 3.3 (Daly Lab
at the Broad Institute, Cambridge, MA) programs.
Functional Genomic Analyses
Electromobility shift (EMS) assays—EMS assays were performed with MCF-7 cell
nuclear extract for oligonucleotides containing the wild type (WT) or variant nucleotides (see
Supplemental Table 1 for oligonucleotide sequences). The procedure has been described
elsewhere (36). 32P-labeled annealed oligonucleotides were incubated with 5 μg nuclear extract
protein (Active Motif, Carlsbad, CA) and 5X binding buffer (Promega Corporation, Madison,
WI) for the binding reactions. Nuclear extract was eliminated from the control reaction. One
hundred-fold excess unlabeled specific oligonucleotide was added to the competition reactions.
All reactions were incubated at room temperature for 20 minutes and were then subjected to
PAGE. The AliBaba2.12 program predicted that the 5′-FR(-628) sequence might bind to
AP2α. Therefore, a supershift assay was also performed with the WT C(-628) oligonucleotides
using a rabbit polyclonal antibody against human AP2α (Santa Cruz Biotechnology, Inc. Santa
Cruz, CA).
Reporter gene studies—The C(-628)T and I1A(701)G, SNPs were located within an area
containing the COMT distal promoter. To study their possible effect on transcription, reporter
gene constructs were created by cloning 1.5 kb of DNA sequence spanning the two SNPs into
pGL3-Basic (Promega). Two single variants, as well as a double variant with both SNPs, were
created from the WT construct by site-directed mutagenesis. Inserts were sequenced in both
directions to ensure that the correct sequence was present. These reporter gene constructs were
designated as the WT, (-628)C/I1(701)A, (-628)T/I1(701)A, (-628)C/I1(701)G and (-628)T/
I1(701)G – the double variant. 1.5 μg of each reporter gene construct was co-transfected with
20 ng of the pRL-TK vector into breast carcinoma MCF-7 cells, MDA468 cells and hepatic
carcinoma HepG2 cells, followed by dual-luciferase assay (Promega). The values for relative
luciferase activity were reported as percentages of the WT activity.
Recombinant COMT expression and enzyme assays—Expression constructs
encoding the WT MB-COMT and S-COMT proteins were generated by cloning the cDNAs
into the eukaryotic expression vector pCR3.1 (Invitrogen, Carlsbad, CA). These expression
constructs were transfected into COS-1 cells and cytosol (containing S-COMT) and microsome
(containing MB-COMT) preparations were isolated (37). COMT activity was measured with
4-hydroxyestradiol and 2-hydroxyestradiol (Sigma-Aldrich, St. Louis, MO) as methyl acceptor
catechol substrates (38). Apparent Km values for 4-OH-E2 and 2-OH-E2 were determined with
a series of substrate concentrations ranging from 0.05 to 20 μM.
COMT exon array analyses—Total RNA was extracted from flash-frozen breast cancer
tissue from 7 individual patients. All RNA samples had an Agilent RNA Integrity Number of
greater than 7.8. The RNA was then reverse-transcribed and biotin labeled for hybridization
2http://www.gene-regulation.com/pub/programs/alibaba2/index.html
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with GeneChip® Human Exon 1.0 ST Arrays (Affymetrix, Santa Clara, CA). Arrays were
normalized with full quantile normalization using XRAY software (Biotique Systems, Inc.,
Reno, NV) and were background corrected using GC-content matched antigenomic probes by
the application of median-polish (exon RMA). Log2 transformed expression values were
derived for each of the COMT “core” probe sets.
Results
COMT Haplotype Structure
COMT was resequenced using DNA samples from 60 Caucasian subjects (22). A total of 33
polymorphisms were observed, including the Val108/158Met polymorphism that has been
studied so often (Fig. 2A). One third of the polymorphisms were located within the region
flanking exon 1, an area that includes the distal promoter for MB-COMT. There appeared to
be at least two clearly defined “haplotype blocks” in DNA samples from CA subjects (Fig.
2B).
Mayo Clinic Breast Cancer Case-Control Association Study
The Mayo Clinic study included 750 cases as well as 732 controls. Characteristics of these
subjects, as well as the GENICA and GESBC subjects, are listed in Supplemental Table 2. For
the Mayo Clinic study, the controls tended to have significantly more live-births than did the
cases, and fewer cases were highly physically active when compared with controls. For the
GENICA study, cases also tended to be less active than controls; but not in the GESBC study,
which recruited younger cases. Finally, cases had a higher frequency of family history of breast
or ovarian cancer than did their controls in all three studies. All SNP genotypes fit HWE
proportions among the controls (p-values ranging from 0.14–0.94 across all three groups),
indicating high-quality genotyping.
Associations of COMT SNPs with case/control status for the Mayo Clinic study are
summarized in Table 1. Two SNPs, rs2020917[C(-628)T] and rs737865 [I1A(701)G],
appeared to be associated with breast cancer risk reduction in premenopausal women. The
analysis was stratified for menopausal status because previous studies of COMT and breast
cancer risk had demonstrated differences between pre- and postmenopausal women (23,25),
and because of a great deal of evidence that the pathophysiology of the disease may differ in
these two groups – including recent data from genome-wide association studies (39–41). The
estimated allele-specific ORs for the rare alleles of both SNPs were approximately 0.70, and
adjustment for covariates had little impact on these estimates. Comparing the log-additive
model of allele effects to the general model for codominant effects did not demonstrate any
statistically significant departures from the log-additive effects. Additional analyses (not
presented) suggested that the effects of these two SNPs did not differ significantly between
ER(+) and ER(−) cases within each of the menopausal strata (p-values ranging from 0.28 to
0.68). These two SNPs were in high LD, both in breast cancer cases (D′ = 0.98 and R2 = 0.95)
and controls (D′ = 0.91 and R2 = 0.78). Although the p-values unadjusted for multiple testing
suggested that these SNPs provide a reduced risk of breast cancer among premenopausal
women (p-value = 0.022 for 5′-FR(-628) and p-value = 0.011 for I1(701)), after correcting for
multiple testing, the associations no longer met the usual criteria for statistical significance (p-
value = 0.201 and 0.102, respectively). However, given the number of studies that have reported
a positive association of COMT with breast cancer, we concluded that these two SNPs were
worth pursuing in replicate studies, especially considering the results of the functional genomic
experiments described subsequently.
The Val108/158Met polymorphism at exon 4(472) that has been studied in all previous
COMT-breast cancer studies did not appear to be associated with breast cancer risk in the Mayo
Ji et al. Page 6
Cancer Res. Author manuscript; available in PMC 2009 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
study. Both of the distal promoter SNPs, 5′-FR(-628) and I1(701), were moderately linked to
the Val108/158Met polymorphism (D′ = 0.78, R2 = 0.21 and D′ = 0.91, R2 = 0.31, respectively)
in the samples used for our COMT resequencing studies.
Functional Genomic Studies
EMS assays and reporter gene studies—The results of the Mayo Clinic study suggested
that the two distal promoter SNPs, 5′-FR(-628) and I1(701), might play a role in breast cancer
risk reduction. However, before attempting replication, we performed a series of functional
genomic experiments to determine the biological plausibility of these SNPs. First, EMS assays
were performed with MCF-7 cell nuclear extract. Fig. 3A shows that nuclear protein(s) bound
to sequences at or near nucleotide (-628), but the change from C to T at that position did not
alter the binding pattern. On the basis of a supershift assay, the protein bound to the (-628)
locus might be an AP2 transcription factor (Fig. 3B). At the I1(701) locus, WT oligonucleotides
did not bind protein, but protein binding occurred with the variant oligonucleotide sequence
(Fig. 3A).
Next, reporter gene studies were performed. Constructs for single variants with each SNP alone
as well as a construct containing both variant nucleotides were created using site-directed
mutagenesis. The double variant had the greatest effect on transcription when compared with
the WT in all three cell lines studied (all p-values <0.002) (Fig. 3C). This effect was particularly
striking in MDA468 cells, with an average 2.3-fold increase (p-value <0.0002).
Substrate kinetic and exon array analyses—Both SNPs that appeared to influence
breast cancer risk were located in the area containing the promoter for MB-COMT. Although
it is known that MB-COMT catalyzes the methylation of catecholamine neurotransmitters with
lower Km values than those for S-COMT (42), there is no similar evidence for
catecholestrogens, so we performed catecholestrogen substrate kinetic studies. Both 2-OH and
4-OH catecholestrogens were substrates for O-methylation catalyzed by MB-COMT (Fig. 4A).
The apparent Km for S-COMT was 16.1 ± 2.0 (mean ± SEM) μM for 4-OH-E2 and 9.0 ± 0.66
μM for 2-OH-E2. MB-COMT had significant lower Km values for both catecholestrogen
substrates, 6.1 ± 0.55 μM for 4-OH-E2 and 1.0 ± 0.04 μM for 2-OH-E2 (p < 0.05 compared
with Km values for S-COMT). We also performed exon array analyses with RNA from breast
cancer tissue to determine whether MB-COMT was expressed in that tissue. Exon array
analyses performed with total RNA extracted from 7 breast cancer tissue samples (Fig. 4B)
showed that the two non-coding upstream exons, exons present only in MB-COMT mRNA,
were expressed in all breast tumor samples.
Results from these functional genomic studies supported a role for MB-COMT and the two
distal promoter SNPs identified during the Mayo Clinic study. This evidence of biological
plausibility provided a stimulus for the replication studies described subsequently.
Replication Studies
The two replication studies performed in collaboration with GENICA and GESBC involved
genotyping only three SNPs (thus reducing multiple testing), the heavily studied
Val108/158Met – exon 4(472) polymorphism and the two distal promoter SNPs. The
association of these SNPs with case-control status in the GENICA and GESBC samples is
illustrated in Table 2. For the GENICA study, the 5′-FR(-628) and I1(701) SNPs were
significantly associated with a reduced risk for breast cancer in the postmenopausal group.
Although the associations of these SNPs in the premenopausal stratum were not statistically
significant by the usual criterion of p-value < 0.05, the sample sizes were much smaller for the
premenopausal stratum, and the magnitude of the allelic effects for the GENICA study were
consistent between the pre- and postmenopausal strata, as well as with the risk reduction
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observed in the Mayo Clinic premenopausal stratum. In contrast, the GESBC study did not
show a risk reduction for these SNPs. In fact, the ORs for that study were slightly greater than
1.0.
Finally, in an attempt to evaluate effect sizes pooled across all three studies, we allowed the
covariates to differ for the three studies (each study was adjusted for its own set of covariates),
but estimated a pooled effect size of the allelic OR for each of the SNPs (see Supplemental
Table 3). Two different p-values are listed: the p-value for OR = 1 tests whether the pooled
OR differs significantly from 1.0, while the p-value for heterogeneity tests whether the ORs
differ across the three studies. The ORs for 5′-FR(-628) and I1(701) differed significantly
among the three studies for the premenopausal stratum. Tables 1 and 2 show that these SNPs
were associated with reduced risk for both the Mayo Clinic and GENICA studies in at least
one of the menopausal cohorts, but displayed no effect in either cohort for the GESBC study.
In contrast, none of the ORs differed significantly in the postmenopausal stratum.
Discussion
Known breast cancer susceptibility genes, including BRCA1 and BRCA2, account for only a
small portion of the familial risk for breast cancer, resulting in many studies with the goal of
identifying low-penetrance risk genes (43). However, most of those efforts were unsuccessful
prior to a recent series of large genome-wide association studies (26,40,41). Those studies
identified common polymorphisms which might represent novel markers for breast cancer risk.
The largest of those studies concluded that many additional common susceptibility alleles
remained to be identified (26). Estrogen exposure is an established breast cancer risk factor
(2,3). COMT could potentially reduce risk for estrogen-dependent carcinogenesis in both ER-
dependent and non-ER-dependent pathways by catalyzing the O-methylation of
catecholestrogens (5,7) (Fig. 1). As a result, numerous breast cancer association studies have
been performed, almost all focusing on the Val108/158Met polymorphism (23–25), and the
results of those studies have been inconsistent.
In the present study, we took a comprehensive approach that began with resequencing of the
COMT gene (Fig. 2A). Fifteen of the 33 polymorphisms identified in DNA from Caucasian
subjects were used to genotype DNA samples from a large Mayo Clinic breast cancer case-
control study. Those 15 polymorphisms were scattered across the entire length of the gene
within both major haplotype blocks present in Caucasian subjects (Fig. 2B). We observed a
reduction in breast cancer risk in premenopausal women associated with two SNPs in the “distal
promoter” for MB-COMT, but the heavily studied Val108/158Met polymorphism failed to
show a significant association with risk.
Functional genomic studies of these two polymorphisms demonstrated that they altered nuclear
protein binding patterns and were associated with the up-regulation of transcription –
potentially resulting in increased COMT activity – compatible with reduced risk if the
“catecholestrogen carcinogenesis hypothesis” is correct. These two SNPs were highly linked,
but both were only moderately linked to the Val108/158Met polymorphism, possibly helping
to explain why that polymorphism has been inconstantly associated with risk. Fig. 2B shows
at least two large haplotype blocks in COMT, and 5′-FR(-628) and I1(701) are both located in
the upstream block associated with MB-COMT. The location of these two functional
polymorphisms in the distal promoter suggested that MB-COMT might play a role in estrogen-
induced carcinogenesis. Previous studies were based on the tacit assumption that S-COMT is
the major isoform in most peripheral tissues, while MB-isoform is most important in the brain
(14,16). However, our substrate kinetic experiments showed that MB-COMT has a higher
affinity for catecholestrogens than does S-COMT (Fig. 4A). Furthermore, exon array analysis
for 7 breast cancer tissue samples indicated that MB-COMT is expressed in breast tumors, with
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expression that might exceed that of S-COMT, thus confirming a previous report that MB-
COMT is expressed in breast cancer tissue (45) (Fig. 4B).
We next extended our studies to include two independent breast cancer case-control studies of
similar ethnic composition. In the GENICA study, the protective effect of the two distal
promoter SNPs was consistent with the Mayo results and that effect was observed for both the
pre- and postmenopausal strata. However, the GESBC study, which consists mainly of
premenopausal subjects, failed to replicate observations made for both Mayo Clinic and
GENICA subjects. Heterogeneity of study results is a constant problem in association studies.
However, our results showed that ORs differed significantly among the premenopausal women
across all three studies. Differences in study design, composition of study populations, and
underlying genetic and/or environmental factors might all contribute to these heterogeneous
results. In addition, the possible effect of one or more undetected confounding factors in the
GESBC study might have diluted the moderate protective role of these COMT variants.
However, it should be emphasized that all of our functional observations were also compatible
with a possible protective role for MB-COMT in estrogen-induced carcinogenesis.
Subsequently, a complementary study was performed using the same Mayo Clinic study, and
one of our two MB-COMT SNPs was also found to be associated with decreased
mammographic density (46), further supporting our hypothesis since decreased
mammographic density is associated with reduced breast cancer risk (47). These distal
promoter SNPs should also be included in future neuropsychiatric studies of COMT.
In summary, we have identified two common, functionally significant polymorphisms located
in the distal promoter of COMT which were associated with breast cancer risk reduction in 2
of 3 independent association studies – studies that included a total of 2327 cases and 2838
controls. Furthermore, laboratory-based functional genomic studies provided strong
mechanistic support for these epidemiologic observations and suggested that the MB-form of
the enzyme might contribute to a possible protective role for COMT in estrogen-induced breast
carcinogenesis.
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Figure 1.
Catecholestrogen-induced carcinogenesis.
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Figure 2.
Human COMT genetic polymorphisms and linkage disequilibrium. (A) COMT genetic
polymorphisms in 60 Caucasian-American (CA) subjects. Arrows indicate the locations of
polymorphisms. Black and gray rectangles represent coding exons, with the grey area specific
for the MB-COMT ORF. Open rectangles represent non-coding exons. ‘I/D’ is insertion/
deletion. Alterations in amino acid sequence resulting from nonsynonymous SNPs are boxed.
Polymorphisms labeled with an asterisk were genotyped in the Mayo Clinic study. (B)
COMT linkage disequilibrium displayed by the use of Haploview 3.3. Polymorphisms with
MAF <5% were excluded from the analysis. The coloring scheme is the standard Haploview
(D′/LOD).
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Figure 3.
COMT functional genomic studies. (A) EMS assays for 5′-FR(-628) and I1(701) SNPs. MCF-7
cell nuclear extract was incubated with 32P-labled oligonucleotides. (B) Supershift assay for
WT 5′-FR(-628). A rabbit polyclonal antibody against the human AP-2α was incubated
with 32P-labled WT 5′-FR (-628) oligonucleotides and MCF-7 cell nuclear extract. (C)
Reporter gene studies. Activities of luciferase reporter gene constructs containing different
combinations of the two loci, 5′-FR(-628) and I1(701), are shown as a percentage of the level
of relative luciferase activity for the WT construct, (-628)C/I1(701)A. Each bar represents the
mean ± SEM of 6 independent transfections.
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Figure 4.
COMT isoform-specific substrate kinetics and expression in breast cancer tissue. (A) Substrate
curves for the methylation of 4-OH-E2 and 2-OH-E2 catalyzed by either MB-COMT or S-
COMT. Each point is the mean ± SEM for 3 determinations. (B) Exon array analysis of COMT
in human breast cancer tissue. Each point represents the normalized expression value for that
probe set. The COMT gene structure is also shown, with blue boxes representing ORF and grey
boxes non-coding exons.
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